Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Milbemycin Oxime,Lufenuron
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Merck Animal Health Acquires US Rights to Sentinel Flavor Tabs & Sentinel From Virbac
Details : Merck Animal Health completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP).
Brand Name : Sentinel
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 02, 2020
Lead Product(s) : Milbemycin Oxime,Lufenuron
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Milbemycin Oxime,Lufenuron
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Details : Merck Animal Health will acquire the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : Milbemycin Oxime,Lufenuron
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?